Interleukin 28 is a potential therapeutic target for sepsis

  • Clin Immunol. 2019 Aug;205:29-34. doi: 10.1016/j.clim.2019.05.012.
Qin Luo  1 ,  Yi Liu  2 ,  Shuang Liu  3 ,  Yibing Yin  3 ,  Banglao Xu  4 ,  Ju Cao  5
Affiliations
  • 1. Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Key Laboratory of Diagnostic Medicine designated by the Ministry of Education, Chongqing Medical University, Chongqing, China.
  • 2. Department of Intensive Care Unit, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • 3. Key Laboratory of Diagnostic Medicine designated by the Ministry of Education, Chongqing Medical University, Chongqing, China.
  • 4. Department of Laboratory Medicine, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.
  • 5. Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Electronic address: [email protected].
PMID: 31121287 DOI: 10.1016/j.clim.2019.05.012
Abstract

Identification of new therapeutic targets for the treatment of sepsis is imperative. We report here that cytokine IL-28 (IFN-λ) levels were elevated in clinical and experimental sepsis. Neutralization of IL-28 protected mice from lethal sepsis induced by cecal ligation and puncture (CLP), which was associated with improved Bacterial clearance and enhanced neutrophil infiltration. Conversely, administration of recombinant IL-28 aggravated mortality, facilitated Bacterial dissimilation and limited neutrophil recruitment, in the model of sepsis induced by CLP. This study defines IL-28 as a detrimental mediator during sepsis and identifies a potential therapeutic target for the immune therapy in sepsis.

Keywords
Immunity; Infection; Interleukin-28; Neutrophil; Sepsis.
Products